Section Arrow
Quote
PMN.NASDAQ
- Promis Neurosciences Inc.
Quotes are at least 15-min delayed:2026/10/18 21:42 EDT
Regular Hours
Last
 8.15
-0.55 (-6.32%)
Day High 
9.64 
Prev. Close
8.7 
1-M High
14.22 
Volume 
20.42K 
Bid
6.01
Ask
12.83
Day Low
7.935 
Open
8.89 
1-M Low
8 
Market Cap 
78.02M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 9.1 
20-SMA 10.47 
50-SMA 12.59 
52-W High 27.4 
52-W Low 6.27 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.62/-5.97
Enterprise Value
81.90M
Balance Sheet
Book Value Per Share
5.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.